Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 04-2020 | 04-2019 | 04-2018 | 04-2017 | 04-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -29,116 | -20,816 | -15,805 | -18,603 | -11,436 |
| Depreciation Amortization | 705 | 378 | 180 | 40 | 33 |
| Accounts payable and accrued liabilities | -1,004 | 1,534 | 217 | -1,599 | 374 |
| Other Working Capital | -20,640 | -18,790 | 25,774 | -4,182 | -210 |
| Other Operating Activity | 5,239 | 1,329 | 192 | 622 | -1,917 |
| Operating Cash Flow | $-44,816 | $-36,365 | $10,558 | $-23,722 | $-13,156 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -220 | -1,081 | -1,427 | -74 | -11 |
| Purchase Of Investment | -49,797 | -79,889 | 0 | 0 | N/A |
| Sale Of Investment | 66,770 | 11,548 | N/A | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | 34,139 | 0 |
| Investing Cash Flow | $16,753 | $-69,422 | $-1,427 | $34,065 | $-11 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -54 | -209 | -151 | 0 | 0 |
| Common Stock Issued | 11,638 | 88,152 | 9,137 | 2 | 33,003 |
| Financing Cash Flow | $11,584 | $87,943 | $8,986 | $2 | $33,003 |
| Exchange Rate Effect | 262 | -1,205 | 1,988 | -1,159 | -598 |
| Beginning Cash Position | 32,006 | 51,055 | 30,950 | 21,764 | 2,526 |
| End Cash Position | 15,789 | 32,006 | 51,055 | 30,950 | 21,764 |
| Net Cash Flow | $-16,217 | $-19,049 | $20,105 | $9,186 | $19,238 |
| Free Cash Flow | |||||
| Operating Cash Flow | -44,816 | -36,365 | 10,558 | -23,722 | -13,156 |
| Capital Expenditure | -220 | -1,081 | -1,427 | -74 | -11 |
| Free Cash Flow | -45,036 | -37,446 | 9,131 | -23,796 | -13,167 |